Latest Pharma and Biotech News
Biotechnology
19 May 2025 Adopting a platform approach to designing new therapies will speed the delivery of innovative genomic treatments to patients—but only if developers, regulators, and manufacturers work together to evolve the current drug development paradigm, writes Vanessa Almendro, vice president of science and technology and head of innovation at Danaher Corporation, in an Expert View piece.
Today's issue
Refine Search
Pharmaceutical
A week after US President Donald Trump signed an executive order to bring back the Most Favored Nation (MFN) idea he introduced at the end of his first term, the US Department of Health and Human Services (HHS announced it is proceeding with implementing the order on prescription drug pricing. 20 May 2025
Pharmaceutical
German drugmaker Grünenthal has named Maren Thurow as its new vice president and head of global communications, stepping into the role at a time of significant business expansion and leadership change. She succeeds Florian Dieckmann, who had led the company’s communications function since 2021. 20 May 2025
Pharmaceutical
Australia’s digital health sector is poised for steady expansion, with the market forecast to grow at a compound annual growth rate of around 8% through 2034, according to research from data and analytics group GlobalData. 20 May 2025
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
Pharmaceutical
Cambridge, USA-based Apnimed today announced positive top-line results from its pivotal Phase III SynAIRgy clinical trial evaluating the efficacy and safety of its lead candidate AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in adults living with mild, moderate and severe OSA, and across all weight classes. 20 May 2025
Biotechnology
German vaccine pioneer BioNTech today revealed that its UK subsidiary has signed a grant agreement with the UK government to broaden the company’s R&D activities for innovative medicines in the UK. 20 May 2025
Biotechnology
Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s Blenrep (belantamab mafodotin) combination for the treatment of adults with relapsed or refractory multiple myeloma. 20 May 2025
Biotechnology
Anti–interleukin five (IL-5) biologics such as mepolizumab and benralizumab have shown significant efficacy in reducing moderate and severe exacerbations in both asthma and chronic obstructive pulmonary disease (COPD), according to new real-world data presented at the 2025 American Thoracic Society (ATS) International Conference. 20 May 2025
Biotechnology
US pharma major Pfizer is stepping up its presence in the high-stakes field of bispecific immuno-oncology with a licensing deal worth up to $6 billion for a Chinese-developed drug that targets two key cancer pathways. 20 May 2025
Pharmaceutical
Major progress has been made in delivering a more efficient and adaptable regulatory framework for clinical trials, and Lawrence Tallon, chief executive of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has reflected on International Clinical Trials Day. 20 May 2025
Pharmaceutical
German drugmaker Boehringer Ingelheim has released full Phase III results for its experimental lung disease drug nerandomilast, showing it met primary endpoints in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
However, while the data were enough to support regulatory filings, analysts remain cautious, viewing the treatment as a marginal improvement over current options. 20 May 2025
Biotechnology
Swiss gene-editing specialist CRISPR Therapeutics and San Diego, USA-based Sirius Therapeutics, which is developing innovative small interfering RNA (siRNA) therapies, announced a strategic partnership to develop and commercialize siRNA therapies. 20 May 2025
Pharmaceutical
Marking International Clinical Trials Day, we bring you a special Q&A with Andrea Manfrin, Deputy Director of Clinical Trials from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). 20 May 2025
Biotechnology
Genetic medicines company Arbor Biotechnologies has announced the appointment of Don Haut as chief business officer. 19 May 2025
Biosimilars
Formycon and its commercialization partner Fresenius Kabi have announced that the US Food and Drug Administration (FDA) has designated FYB202/Otulfi (ustekinumab-aauz) as interchangeable with Johnson & Johnson’s (NYSE: JNJ) reference biologic Stelara (ustekinumab). 19 May 2025
Biotechnology
Cambridge, UK-based CellCentric today announced the completion of a $120 million Series C funding round. 19 May 2025
Pharmaceutical
A US district court judge has found that the Department of Health and Human Services (HHS) must preapprove the use of 340B rebate models before they can be implemented. 19 May 2025
Biotechnology
US human genetics biotech 23andMe today revealed it has entered into a definitive agreement for the sale of the company to Regeneron Pharmaceutical, whose shares climbed 2% following the announcement 19 May 2025
All news
Pharmaceutical
Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, following the implementation of Veeva Systems' Development Cloud. 12 March 2025
Pharmaceutical
ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 and VH499. 12 March 2025
Pharmaceutical
Shares of Danish biotech Zealand Pharma were up 30% at 635.50 kroner by early afternoon, on news of a potentially lucrative licensing deal with Swiss pharm giant Roche. 12 March 2025
Pharmaceutical
US biopharma Viking Therapeutics developing therapies for metabolic and endocrine disorders, closed Tuesday’s trading 5% lower. 12 March 2025
Pharmaceutical
California commercial-stage biopharma firm Geron Corporation has announced that Dr John “Chip” Scarlett, president, chief executive (CEO) and chairman, will depart the company on March 31, 2025. 12 March 2025
Biotechnology
UK-based Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today announces the appointment of Haseeb Ahmad as its chief executive (CEO) and member of the board of directors effective immediately. 12 March 2025
Biotechnology
Independent French drugmaker Pierre Fabre Laboratories and Switzerland-based RedRidge Bio have announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. 12 March 2025
Biotechnology
Italian biomedical charity Fondazione Telethon, which is focused on rare genetic diseases, revealed it has submitted a Biologics License Application (BLA) for the gene therapy - etuvetidigene autotemcel – as a treatment of patients with Wiskott-Aldrich syndrome (WAS), a rare genetic disease of the immune system, to the US Food and Drug Administration (FDA). 12 March 2025
Generics
Rajeev Juneja, vice chairman and managing director of Mumbai, Indian-based drugmaker Mankind Pharma, today announced that the company is launching the generic version as well as its fixed dose combination (FDCs) of diabetes drug empagliflozin in India, at a 90% discount to the originator, Boehringer Ingelheim’s drug, Jardiance. The news came as empagliflozin lost patent protection in India. 12 March 2025
Pharmaceutical
In this week’s podcast, we welcome Ido Peleg, CEO and Co-Founder of Yonalink, who provides insights into the current and future state of the clinical trial industry. 11 March 2025
Biotechnology
Harbour BioMed has appointed Michael Patten as chief strategy officer, responsible for overseeing global corporate development and growth strategy. He will also lead the company's global alliance efforts, focusing on expanding its presence in key markets outside China. 11 March 2025
Pharmaceutical
Alliance Pharma has accepted a final increased cash offer from investment firm DBAY Advisors, valuing the UK-based pharmaceutical company at approximately £362 million ($468 million). 11 March 2025
Pharmaceutical
USA-based Endo Inc today announced it has entered into a definitive agreement to divest its international pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma to Knight Therapeutics. 11 March 2025
Biotechnology
Privately-held Tenpoint Therapeutics, a UK-headquartered biotech focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, has announced the appointment of Carol Kearney as chief commercial officer (CCO). 11 March 2025
Biotechnology
Shares of US biotech 2seventy Bio skyrocketed almost 76% to $4.92 today, as it agreed to a takeover bid from US pharma major Bristol Myers Squibb, which is looking to enhance its CAR T-cell therapy business. 11 March 2025
Pharmaceutical
A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and tirzepatide leads to significant reductions in HbA1c levels and body weight among adults with type 1 diabetes (T1D). 11 March 2025
Biotechnology
Sino-American biopharma Ascentage Pharma has announced that olverembatinib has been granted Breakthrough Therapy Designation (BTD) by China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), alongside low-intensity chemotherapy, for first-line treatment of newly-diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). 11 March 2025
Biotechnology
The market for Bavencio (avelumab), the checkpoint inhibitor co-developed by Pfizer and Merck KGaA, continues to grow as new indications drive demand. 11 March 2025
Biotechnology
Danish cancer specialist Genmab’s stock took a hit after US healthcare giant Johnson & Johnson opted not to license its HexaBody-CD38 (GEN301), despite its promising trial results. 11 March 2025
Biotechnology
US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the shape of icotrokinra. 11 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze